Novo Nordisk Shares Rise After Fda Approves Wegovy for Liver Disease | Nvo stock price
Novo Nordisk Shares Surge with much of 5% in Early European Trading Following The Us Food and Drug Administration’s Approval of its Blockbuster Weight -los Drug Wegovy for Treating A Serious Liver